The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.